|
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The expressions of tumor necrosis factor (TNF)-α, interleukin (IL)-6, B-cell lymphoma (Bcl)-2 associated X protein (Bax), and caspase-3 in the PFC-PL of OB rats were significantly increased as compared with the sham rats, but the Bcl-2 and IL-10 expressions were decreased, whereas BI-1 overexpression significantly suppressed the changes of these proteins in the PFC-PL of OB rats.
|
30735101 |
2019 |
|
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Compared with those in the model group, the necrosis of bone tissues significantly decreased, the apoptosis level of osteocytes remarkably declined (p<0.01), the content of IL-1β, IL-6 and TNF-α in bone tissues markedly decreased (p<0.01), the content of IL-10 increased (p<0.01), the expression level of cleaved caspase-3 protein in bone tissues significantly declined (p<0.01), the B-cell lymphoma 2/BCL2-Associated X (Bcl-2/Bax) expression level markedly increased (p<0.01) and the expression levels of ALK3, GATA4 and NKX2.5 in bone tissues significantly decreased (p<0.01) in the intervention group.
|
31210286 |
2019 |
|
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The levels of AQP9 and inflammatory factors [tumour necrosis factor-α (TNF-α), interleukin-6 (IL-6), interleukin-10 (IL-10)] in peripheral blood of rats were detected by ELISA method. qRT-PCR and western blot were used to detect the mRNA and protein expression of AQP9, ERK1/2, B-cell lymphoma-2 (Bcl-2), Bcl-associated x (Bax) in the myocardial tissue of rats.
|
31218464 |
2019 |
|
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Levels of interferon γ (IFN-γ), interleukin 10 (IL-10), interleukin 6 (IL-6), tumor necrosis factor α (TNF-α), creatine kinase (CK), lactate dehydrogenase (LDH), superoxide dismutase (SOD) and malondialdehyde (MDA) were detected, and expression of miR-203, MYD88, toll-like receptor 4 (TLR4), Faslg, Cleaved-Caspase-3, B-cell lymphoma 2 (Bcl-2) and Bcl-2-associated X protein (Bax) was evaluated.
|
30772517 |
2019 |
|
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our study demonstrated that STMN RNA interference (RNAi) enlarged taxol-induced inhibitions in cellular proliferation, colony formation, and multidimensional spaces of cell immigration and decreased half maximal inhibitory concentration (IC<sub>50</sub>) of taxol in nonsmall cell lung cancer (NSCLC) NCI-H1299 cells; STMN RNAi and taxol jointly attenuated the expressions of extracellular regulated kinase (ERK), nuclear factor kappa B (NF-κB) and B cell lymphoma-2 (Bcl-2), but up regulated Bax expression and initiated intrinsic cell death pathway by activating caspase-3 and caspase-9, while inhibited interleukin 10 (IL-10) autocrine from cell culture supernatant and xenografted mouse serum, as well as intracellular expressions of IL-10 protein and mRNA in vitro; additionally, neutralizing IL-10 alone would incur cell apoptosis to some degree; the further study confirmed that RNAi targeting STMN promoted the sensitivity of taxol in different NSCLC cells.
|
28589243 |
2018 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
Pro-apoptotic BCL-2 inhibitor A-1211212 diminishes lymphocytes and ameliorates colitis in Il10-/- mice without inducing thrombocytopenia.
|
29745420 |
2018 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
Previous data demonstrate that Epstein-Barr Virus Latent Membrane Protein 2A (LMP2A) enhances IL-10 to promote the survival of LMP2A-expressing B cell lymphomas.
|
27792904 |
2017 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
End point polymerase chain reaction was performed for interleukin-1β, interleukin-10, stem cell factor, transforming growth factor-β, high-mobility group box-1 (HMGB-1), and B-cell lymphoma-extra large.
|
28624051 |
2017 |
|
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression levels of proapoptotic protein (Bcl-2-associated X protein) and proinflammatory cytokines (tumor necrosis factor alpha and interleukin [IL]-1β) were significantly decreased after MSCs-exosomes treatment, whereas expression levels of antiapoptotic (B-cell lymphoma 2) and anti-inflammatory (IL-10) proteins were upregulated.
|
28665182 |
2017 |
|
B-Cell Lymphomas
|
0.100 |
GeneticVariation
|
group |
BEFREE |
IL-10-3575T/A and -1082A/G polymorphisms were associated with altered NHL susceptibility, especially for Caucasians and B cell lymphoma.
|
27006334 |
2016 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
Overexpression of microRNA-194 attenuates IL-10 production and increases apoptosis of EBV(+) B cell lymphoma lines.
|
26147452 |
2015 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
Hence, IL-10R deficiency is associated with a high risk of developing B-cell lymphoma.
|
24089328 |
2013 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
Epstein-Barr virus LMP2A increases IL-10 production in mitogen-stimulated primary B-cells and B-cell lymphomas.
|
23303827 |
2013 |
|
B-Cell Lymphomas
|
0.100 |
GeneticVariation
|
group |
BEFREE |
IL10 rs1800896 was associated with B cell lymphoma [per-allele odds ratio (OR) = 1.25, 95 % confidence interval (CI) 1.08-1.45; p trend = 0.003], specifically diffuse large B cell lymphoma (DLBCL) (per-allele OR = 1.29, 95 % CI 1.08-1.53; p trend = 0.004), as well as T cell lymphoma (per-allele OR = 1.44, 95 % CI 1.13-1.82; p trend = 0.003).
|
23640160 |
2013 |
|
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
LHGDN |
Correlation of serum IL-6, IL-8 and IL-10 levels with clinicopathological features and prognosis in patients with diffuse large B-cell lymphoma.
|
18479302 |
2008 |
|
B-Cell Lymphomas
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Analysis of 4 SNPs in the IL10 promoter (-3575T>A, -1082A>G, -819C>T, and -592C>A) revealed that both the AGCC haplotype (odds ratio [OR] = 1.54, 95% confidence interval [CI] = 1.21-1.96, P < .001) and the TATA haplotype (OR = 1.37, 95% CI = 1.05-1.79, P = .02) were associated with increased risk for B-cell lymphomas.
|
16449530 |
2006 |
|
B-Cell Lymphomas
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In this study, we determined the genotypic and allelic frequencies of the Interleukin (IL)-10(-1082G/A) IL-10(-592A/C), and IL-10(-819C/T) polymorphisms, and their association with the risk to develop B cell Non Hodgkin Lymphoma (NHL) in hepatitis virus C (HCV) carriers.
|
17049666 |
2006 |
|
B-Cell Lymphomas
|
0.100 |
GeneticVariation
|
group |
LHGDN |
The interleukin-10 gene promoter polymorphism (-1082) does not correlate with clinical outcome in diffuse large B-cell lymphoma.
|
15933064 |
2005 |
|
B-Cell Lymphomas
|
0.100 |
GeneticVariation
|
group |
LHGDN |
Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma.
|
14701701 |
2004 |
|
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Non-Hodgkin's B cell lymphoma in persons with acquired immunodeficiency syndrome is associated with increased serum levels of IL10, or the IL10 promoter -592 C/C genotype.
|
14597210 |
2003 |
|
B-Cell Lymphomas
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We analysed the frequencies of three single base substitutions in the IL-10 promoter in patients with aggressive lymphoma (B-cell DLCL n = 46, other aggressive histologies n = 17), Hodgkin's disease (n = 44) or low/intermediate grade lymphoma (n = 46), compared to healthy controls.
|
12688341 |
2003 |
|
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
HLA-G protein up-regulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas.
|
11781245 |
2002 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results further the understanding of how the IL-10 gene could be regulated in B cell lymphomas.
|
11196656 |
1999 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
B cell IL-10 may function as autocrine growth factor for B cell lymphomas, and both IL-10 and BCRF1 seem to be involved in the pathophysiology of non-Hodgkin's lymphomas.
|
8167552 |
1994 |
|
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
To date, IL-10 expression has been described in several T clones induced with anti-CD3 and phorbol myristate acetate (PMA), in monocytes stimulated with lipopolysaccharide (LPS), and in murine B-cell lymphomas.
|
1325212 |
1992 |